El-Kaissi Samer, Sherbeeni Suphia
Specialized Diabetes & Endocrine Centre, King Fahad Medical City, Riyadh, Saudi Arabia.
Curr Diabetes Rev. 2011 Nov;7(6):392-405. doi: 10.2174/157339911797579160.
While lifestyle modifications and metformin are the cornerstone of the initial management of type 2 diabetes mellitus, there is an increasing array of second and third-line pharmacological agents for this condition. These include sulphonylureas, insulin, thiazolidinediones and alpha-glucosidase inhibitors, with the more recent addition of glucagon- like peptide-1 agonists, dipeptidyl peptidase-IV inhibitors and pramlintide. Moreover, insulin analogues that better simulate endogenous insulin secretion have been developed. This review aims to provide an update on the current pharmacological management of type 2 diabetes mellitus, and to highlight the benefits and limitations of each treatment.
虽然生活方式的改变和二甲双胍是2型糖尿病初始治疗的基石,但针对这种疾病的二线和三线药物治疗药物越来越多。这些药物包括磺脲类、胰岛素、噻唑烷二酮类和α-葡萄糖苷酶抑制剂,最近又增加了胰高血糖素样肽-1激动剂、二肽基肽酶-4抑制剂和普兰林肽。此外,还开发出了能更好模拟内源性胰岛素分泌的胰岛素类似物。本综述旨在提供2型糖尿病当前药物治疗的最新情况,并强调每种治疗方法的益处和局限性。